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Purpose: To report an association between prostate cancer and vitamin D levels among different races in a 
single population in the United States.
Materials and Methods: We investigated whether there was an association between vitamin D level and prostate 
cancer in different races in the United States. We used data collected from 1,363 men during the National Health 
and Nutrition Examination Survey 2007–2008. Multivariate logistic regression analysis was used to evaluate the 
independent associations between vitamin D levels (not only 25-hydroxyvitamin D [25(OH)D], but also 25(OH)D2 
and D3) and prostate cancer. Association between vitamin D levels and prostate specific antigen level was also 
analyzed in non-Hispanic white males without prostate cancer.
Results: Older age was significantly associated with prostate cancer in all races (p＜0.05), whereas vitamin D 
(p=0.024), especially 25(OH)D2 (p=0.027) was significantly higher only in non-Hispanic white males. There was 
no difference in vitamin D levels between non-Hispanic white males with a prostate specific antigen concentration 
＞3 ng/mL and ≤3 ng/mL.
Conclusions: This study revealed a positive association between vitamin D, especially 25(OH)D2, and prostate 
cancer only in non-Hispanic white males. And vitamin D was not associated with prostate specific antigen level 
causing detection bias. (Korean J Urol Oncol 2020;18:32-39)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
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INTRODUCTION
Prostate cancer is the most common malignant cancer af-
fecting adult males in the United States, but the etiological 
factors for prostate cancer are not completely understood. 
Vitamin D is a fat-soluble vitamin produced by exposure 
to sunlight or obtained from the diet. The biological func-
tions of vitamin D include participation in bone metabolism 
and remodeling and antiproliferative and antiangiogenic 
effects.1 Many studies have revealed that vitamin D has pro-
tective effects against the development of prostate cancer.2-4 
However, the results of a recent meta-analysis suggest that 
there is a positive association between higher levels of vita-
min D and prostate cancer risk.5
Vitamin D levels are affected by skin pigmentation, 
which differs according to race. Levels of vitamin D are 
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also determined by diet, which differs between and within 
Western and Asian populations. In the United States, the 
incidence rates of prostate cancer are 70% greater in 
African American compared with non-Hispanic white 
populations. African American populations have lower 
mean circulating 25-hydroxyvitamin D levels.6
We investigated whether there was association between 
vitamin D status, which was assessed using serum 
25-hydroxyvitamin D (25(OH)D) concentrations, and pros-
tate cancer in different races. We used data from the 
National Health and Nutrition Examination Survey 
(NHANES) 2007–2008 for the analysis.
MATERIALS AND METHODS
1. Study Population
The NHANES is an ongoing cross-sectional observational 
study that collects health-related information using multi-
stage probability sampling of the civilian, non-in-
stitutionalized United States population. The Institutional 
Review Board of the National Center for Health Statistics 
approved the protocol for the NHANES. Informed consent 
was obtained from all participants. We used data obtained 
from male participants (≥40 years of age), which was ob-
tained during the 2007–2008 NHANES cycle.
NHANES datasets can be downloaded at NHANES web-
site (https://wwwn.cdc.gov/nchs/nhanes). The questionnaires, 
data sets, and related documentation page lists all the survey 
cycles from the most recent to most historic. We used the 
current NHANES, also known as continuous NHANES, 
which refers to the 2-year cycles of data produced since 
1999. Each cycle is divided into 5 sections labeled by col-
lection method: demographics, dietary, examination, labo-
ratory, and questionnaire. We could select specific variables 
to be included in our analysis by downloading specific files. 
All information regarding which files contain specific varia-
bles are listed on documentation files.
2. Measurement and Classification of Variables
Serum 25(OH)D metabolites were measured at a Centers 
for Disease Control laboratory using the Diasorin assay. The 
total serum 25(OH)D (nmol/L) concentration was calculated 
as the sum of 25(OH)D3 and 25(OH)D2, excluding the 
C3-epi-25(OH)D3 metabolite. Vitamin D data were col-
lected as part of the NHANES in the southern United States 
during the winter months and in the northern United States 
during the summer months. Serum total cholesterol concen-
tration was measured using an enzyme-based assay. In the 
men diagnosed with prostate cancer, all variables were 
measured after the diagnosis of prostate cancer. Since pros-
tate specific antigen (PSA) varies with treatments, PSA was 
not evaluated in those with prostate cancer or prostatitis. 
Men who had prostate manipulation (e.g., prostate biopsy, 
surgery, or cystoscopy) within 1 month or rectal examination 
within 1 week were also excluded from PSA evaluation. The 
serum total PSA level was measured using the Hybritech 
method (Beckman Access, Fullerton, CA, USA).
Body mass index (BMI) was calculated as body weight 
in kilograms divided by height in meters squared. Dietary 
calcium and vitamin D intake amounts were based on a sin-
gle 24-hour dietary recall.
3. Subgroup Analysis
Each participant was assigned by race to one of 3 groups 
(i.e., non-Hispanic white, non-Hispanic black, and Others 
[e.g., Mexican American and Hispanic]). There were limited 
numbers of participants in the non-White race groups. 
Therefore, the vitamin D and PSA subgroups were confined 
to the non-Hispanic white group. The vitamin D intervals 
were taken from Tuohimaa et al.,7 who described the 
U-shape of prostate cancer risk. The PSA cut point of 3.0 
ng/mL was set using National Comprehensive Cancer 
Network guidelines8 and subgroup analysis by PSA was 
done on only non-Hispanic white males without prostate 
cancer, and who have PSA results available.
4. Statistical Analysis
The results were reported as mean (standard deviation) 
values for continuous variables and as percentage values for 
categorical variables. For the univariate analysis, t-tests and 
analysis of variance were used to compare continuous 
variables. A multivariate logistic regression model was used 
to evaluate the association between prostate cancer and vita-
min D level after adjusting for potential confounding factors 
that were related to an increased prostate cancer risk. We 
used multivariate models of logistic regression that included 
all risk factors that were revealed to be statistically sig-
nificant by the univariate analysis and evaluated odds ratios 
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Age (yr) 62.8±12.7 59.2±10.9 57.3±11.5 ＜0.001
Weight (kg) 90.2±19.1 89.9±21.5 83.0±15.8 ＜0.001
Body mass index (kg/m2) 29.1±5.5 29.2±6.5 29.1±4.6 0.997
Total cholesterol (mg/dL) 190.4±41.4 198.2±41.3 205.1±42.0 ＜0.001
Calcium (mg/day)* 954.8±568.3 737.8±471.7 903.6±570.9 ＜0.001
Vitamin D (25(OH)D2+25(OH)D3)* (g/day) 4.9±5.4 3.6±5.9 4.7±4.6 0.004
25(OH)D (nmol/L) 71.3±20.7 44.5±18.4 58.3±17.6 ＜0.001
  25(OH)D2 (nmol/L) 5.6±9.4 4.5±8.3 3.5±6.0 0.001
  25(OH)D3 (nmol/L) 65.7±21.2 40.0±17.7 54.8±17.2 ＜0.001
Prostate cancer 48 (6.3) 26 (10.2) 5 (1.4) ＜0.001
Values are presented as mean±standard deviation or number (%).
25(OH)D2: 25-hydroxyvitamin D2, 25(OH)D3: 25-hydroxyvitamin D3.
*Calcium and vitamin D indicate the amount taken by the diet. †These include those with prostate cancer and those without. 
‡p-value calculated using analysis of variance.
(ORs) by adjusting for potential confounders using a series 
of models. In the non-Hispanic white males without prostate 
cancer, multivariate logistic regression model was used to 
explain the relationship between PSA ＞3 ng/mL and other 
variables in the same way.
IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, 
USA) was used for the statistical analyses. All statistical 
tests were two-tailed, and a p-value ＜0.05 was considered 
to indicate a statistically significant result.
RESULTS
The baseline characteristics of the study population are 
presented in Table 1. Among the 1,363 participants, 55.6% 
were non-Hispanic white. The percent who had a prostate 
cancer diagnosis in the non-Hispanic white group was 6.3% 
compared with 10.2% in the non-Hispanic black group. 
There were no differences in BMI between the 3 groups. 
The distribution in vitamin D level indicated that most of 
the non-Hispanic white males had adequate levels of vitamin 
D (i.e., ≥20 ng/mL [49.9 nmol/L], Institute of Medicine).9 
Consistent with previous study results, vitamin D levels 
were significantly lower in the non-Hispanic black group 
compared with the other races.6 The groups with vitamin 
D levels <40 nmol/L had no prostate cancer compared with 
the groups with vitamin D levels ≥40 nmol/L (Table 2).
The results of the univariate and multivariate analyses in-
dicated that non-Hispanic whites with a prostate cancer 
were significantly older and had higher 25(OH)D2 levels 
compared to those without a prostate cancer (Table 3). 
Older age was significantly associated with prostate cancer 
in the group of non-Hispanic blacks. However, 25(OH)D2 
and 25(OH)D3 levels were not associated with prostate can-
cer (Table 4). Also, in the Others group, the results of uni-
variate and multivariate analyses revealed that older age 
was significantly associated with prostate cancer (Table 5).
Among 710 non-Hispanic white males without prostate 
cancer, 688 men who have PSA results available were in-
cluded in the subgroup analysis by PSA. The results of the 
univariate analysis indicated that the members of the 
non-Hispanic white group with a PSA level ＞3 ng/mL 
were significantly older and had lower body weights, lower 
calcium intakes, and higher 25(OH)D2 levels compared 
with those with PSA levels ≤3 ng/mL. However, age was 
the only statistically significant factor in the multivariate 
analysis (Table 6).
DISCUSSION
The results of our analysis indicated that in non-Hispanic 
white males, higher vitamin D levels were significantly and 
independently associated with prostate cancer, even after 
adjustment for multiple potential confounding variables. To 
the best of our knowledge, this study of a United States 
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　≤19 (n=2) 　20–39 (n=34) 40–59 (n=180) 60–79 (n=308) 　≥80 (n=234) 　
Age (yr) 70.0±14.1 61.8±9.8 62.2±13.1 63.0±13.1 63.0±12.2 0.841
Weight (kg) 112.1±43.2 93.6±25.7 92.7±20.2 90.3±18.2 87.3±17.6 0.015
Body mass index (kg/m2) 34.2±11.6 30.6±8.1 29.9±5.3 29.2±5.2 28.2±5.1 0.005 
Total cholesterol (mg/dL) 176.5±5.0 193.3±49.2 187.8±43.0 190.0±40.1 192.5±41.0 0.779
Calcium (mg/day)* 670.5±430.6 912.2±668.2 873.9±479.4 962.1±560.6 1,015.9±620.3 0.130
Vitamin D (25(OH)D2+
25(OH)D3)* (g/day)
2.7±1.7 3.4±3.7 4.1±3.7 5.0±6.1 4.9±5.4 0.017
25(OH)D (nmol/L) 1.5±0.0 1.6±0.4 3.8±5.9 5.8±9.0 7.2±12.0 ＜0.001
  25(OH)D2 (nmol/L) 13.6±4.5 28.8±4.9 47.7±7.6 63.7±10.5 87.9±17.3 ＜0.001
  25(OH)D3 (nmol/L) 　 0 (0) 　 0 (0) 10 (5.6) 17 (5.5) 　 21 (9.0) 　 0.222
Values are presented as mean±standard deviation or number (%).
25(OH)D2: 25-hydroxyvitamin D2, 25(OH)D3: 25-hydroxyvitamin D3.
*Calcium and vitamin D indicate the amount taken by the diet. †p-value calculated using analysis of variance.
Table 3. Characteristics of non-Hispanic white males by prostate cancer history
Characteristic　
Never been diagnosed 





p-value† p-value‡ OR (95% CI)
Age (yr) 62.0±12.6 74.4±6.8 ＜0.001 ＜0.001
Weight (kg) 90.4±19.2 87.1±16.4 0.257
Body mass index (kg/m2) 29.2±5.6 28.4±4.2 0.344
Total cholesterol (mg/dL) 190.7±41.5 184.9±39.2 0.345
Calcium (mg/day)* 955.9±571.6 938.0±522.9 0.833
Vitamin D (25(OH)D2+25(OH)D3)* 
(g/day)
4.9±5.5 4.8±3.5 0.164
25(OH)D (nmol/L) 70.8±20.5 78.2±22.1 0.015 0.024 1.017 (1.002–1.032)†
  25(OH)D2 (nmol/L) 5.2±9.1 10.6±11.7 0.003 0.027 1.026 (1.003–1.050)†
  25(OH)D3 (nmol/L) 65.5±21.0 67.7±24.2 0.497 　
Values are presented as mean±standard deviation.
25(OH)D2: 25-hydroxyvitamin D2, 25(OH)D3: 25-hydroxyvitamin D3.
*Calcium and vitamin D indicate the amount taken by the diet. †p-value calculated using t-test. ‡p-value calculated using logistic 
regression for multivariate analysis.
population is the first to compare differences in vitamin D 
levels with prostate cancer among different races.
There have been conflicting data in terms of the prostate 
cancer risk according to serum vitamin D levels. Our result 
that there was a significant positive association between 
25(OH)D2 levels and prostate cancer in non-Hispanic white 
males is not consistent with the results of previous studies 
that found that higher vitamin D levels have a beneficial 
role.2-4,10,11 However, several recent studies have found that 
elevated vitamin D levels increase the risk of prostate 
cancer.5,12-14 The mechanisms that contribute to the associa-
tion between greater 25(OH)D levels and prostate cancer 
development are unclear. However, we can speculate that 
at higher levels, 25(OH)D displaces 1,25(OH)2D from vita-
min D binding protein. Pettifor et al. and others have found 
that an increase in free 1,25(OH)2D can result from dis-
placement from vitamin D binding protein by higher 
25(OH)D levels.15-17 1,25(OH)2D inhibits cell proliferation, 
angiogenesis, and other metabolic activities. Therefore, the 
subsequently lower levels of 1,25(OH)2D that result from 
25(OH)D binding to vitamin D binding protein may pro-
mote prostate cancer development.
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Table 4. Characteristics of non-Hispanic black males by prostate cancer history
Characteristic
Never been diagnosed with 
prostate cancer (n=230)
Diagnosed with prostate 
cancer (n=26)
p-value† p-value‡
Age (yr) 58.2±10.8 68.8±7.3 ＜0.001 ＜0.001
Weight (kg) 89.9±22.1 90.1±15.5 0.967
Body mass index (kg/m2) 29.1±6.7 30.0±5.5 0.504
Total cholesterol (mg/dL) 198.4±41.7 196.2±38.8 0.796
Calcium (mg/day)* 749.2±483.6 637.0±339.4 0.251
Vitamin D (25(OH)D2+25(OH)D3)* (g/day) 3.3±3.3 6.3±15.6 0.339
25(OH)D (nmol/L) 43.9±18.6 49.8±16.1 0.122
  25(OH)D2 (nmol/L) 4.6±8.6 3.5±5.3 0.540 
  25(OH)D3 (nmol/L) 39.3±17.8 46.2±15.9 0.058 　
Values are presented as mean±standard deviation.
25(OH)D2: 25-hydroxyvitamin D2, 25(OH)D3: 25-hydroxyvitamin D3.
*Calcium and vitamin D indicate the amount taken by the diet. †p-value calculated using t-test. ‡p-value calculated using logistic 
regression for multivariate analysis.
Table 5. Characteristics of the Others group (Mexican American and Hispanic) by prostate cancer history
Characteristic
Never been diagnosed with 
prostate cancer (n=344)
Diagnosed with prostate 
cancer (n=5)
p-value† p-value‡
Age (yr) 57.0±11.4 73.4±5.4 0.001 0.011
Weight (kg) 83.0±15.8 80.7±17.4 0.740 
Body mass index (kg/m2) 29.1±4.6 29.2±4.2 0.956 
Total cholesterol (mg/dL) 205.6±41.8 176.4±51.7 0.124 
Calcium (mg/day)* 909.0±572.8 535.8±229.4 0.147 
Vitamin D (25(OH)D2+25(OH)D3)* (g/day) 4.7±4.6 2.6±3.0 0.319 
25(OH)D (nmol/L) 58.4±17.6 50.1±22.5 0.296
  25(OH)D2 (nmol/L) 3.5±6.0 2.4±2.2 0.682 
  25(OH)D3 (nmol/L) 54.9±17.2 47.7±21.6 0.354 
Values are presented as mean±standard deviation.
25(OH)D2: 25-hydroxyvitamin D2, 25(OH)D3: 25-hydroxyvitamin D3.
*Calcium and vitamin D indicate the amount taken by the diet. †p-value calculated using t-test. ‡p-value calculated using logistic 
regression for multivariate analysis.
25(OH)D consists of 25(OH)D2 and 25(OH)D3, which 
are the 2 significant forms of vitamin D. 25(OH)D2 have 
the same effects on prostate cancer growth inhibition but 
with fewer hypercalcemia-related side effects. Therefore, 
many studies have exploited the efficacy of 25(OH)D2.18-21 
Some of the studies have analyzed total 25(OH)D without 
separating 25(OH)D2 and 25(OH)D3. Unlike previous stud-
ies, we analyzed 25(OH)D2 and 25(OH)D3 separately in 
this study. 25(OH)D2 (ergocalciferol) is a plant-based sterol 
found in fungi that occur on roughage. 25(OH)D3 
(cholecalciferol) is animal-based sterol that can be obtained 
from vitamin supplements or from endogenous synthesis in 
the skin. Our study results indicated that only 25(OH)D2 
level was significantly associated with prostate cancer in 
non-Hispanic white males. Normal and malignant prostate 
cells contain vitamin D receptor, which mediates the anti-
proliferative action of 1,25 (OH)2D3.
22,23 However, 1,25 
(OH)2D3 and 1,25(OH)2D2 have similar dose-dependent in-
hibition effects on prostate cancer cells.24 Therefore, we can 
infer that although both 25(OH)D2 and 25(OH)D3 are re-
lated to prostate cancer, the main risk factor is most likely 
to be 25(OH)D2 level because the differences in 25(OH)D3 
are not statistically significant between those with and with-
out prostate cancer. 25(OH)D2 and 25(OH)D3 levels have 
not been analyzed separately in most studies.1,4,5,7,12 
Therefore, 25(OH)D2 and 25(OH)D3 should be studied in-
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Age (yr) 60.0±12.5 71.2±8.1 ＜0.001 ＜0.001
Weight (kg) 91.3±19.5 85.5±17.4 0.003 0.347
Body mass index (kg/m2) 29.3±5.6 28.5±5.1 0.160 
Total cholesterol (mg/dL) 191.1±41.1 193.0±44.2 0.647 
Calcium (mg/day)* 983.0±595.3 845.5±440.1 0.005 0.601
Vitamin D (25(OH)D2+25(OH)D3)* (g/day) 5.0±5.3 4.8±6.6 0.695 
25(OH)D (nmol/L) 4.9±9.0 6.9±9.7 0.046 0.396
25(OH)D2 (nmol/L) 65.5±21.3 67.0±19.8 0.496 　
Values are presented as mean±standard deviation.
25(OH)D2: 25-hydroxyvitamin D2, 25(OH)D3: 25-hydroxyvitamin D3.
*Calcium and vitamin D indicate the amount taken by the diet. †p-value calculated using t-test. ‡p-value calculated using logistic 
regression for multivariate analysis. §Only non-Hispanic white males without prostate cancer history who have prostate specific 
antigen results available are included.
dividually, and future studies are warranted to further inves-
tigate the role of 25(OH)D2, which is just almost 10 percent 
of 25(OH)D3.
In Table 3, it seems that higher vitamin D levels in pros-
tate cancer are due to the older age because the older age 
is the significantly associated with prostate cancer. However, 
because there were no significant differences in age between 
the vitamin D levels in Table 2, we could know that higher 
vitamin D level is not due to the older age.
In the NHANES study, PSA levels were not evaluated 
in men with prostate disorders, including prostate cancer; 
men with prostate cancer were excluded from the analysis 
of the relationship between vitamin D and PSA level. In 
our multivariate analysis, vitamin D was not associated with 
PSA level causing detection bias, similar to the research by 
Anic et al.,25 which found that PSA concentration is not as-
sociated with serum 25(OH)D using NHANES 2001–2006 
data.
Calcium and vitamin D intake are not associated with 
prostate cancer. Studies that examine the effects of vitamin 
D and calcium in different races, especially in Asian pop-
ulations, are needed because few studies have been 
published.26-29 The relationship between adiposity and pros-
tate cancer risk has been extensively investigated but re-
mains unclear. The results of some studies have not sup-
ported adiposity as a risk factor for prostate cancer, but a 
recent meta-analysis found that there is a positive associa-
tion between BMI and prostate cancer risk.30,31 However, 
the results of our study indicated that there was no associa-
tion between BMI and prostate cancer for any race group.
This study had several limitations. First, because we used 
a cross-sectional study design, the presence of a causal rela-
tionship could not be evaluated. Second, the NHANES 
study excluded individuals with a prostate cancer from the 
evaluation of PSA. Therefore, a broad analysis of the rela-
tionship between PSA and vitamin D levels in prostate can-
cer patients could not be performed. Third, in the prostate 
cancer patients, all variables were measured after the pros-
tate cancer diagnosis. However, we could not get the exact 
information about the interval between the prostate cancer 
diagnosis and the variables measurement, and the prostate 
cancer treatment and physical activity related to prostate 
cancer disease status might have affected vitamin D levels. 
Blood samples taken before a prostate cancer diagnosis 
should be used to examine the contributions of 25(OH)D2 
and 25(OH)D3. Further analyses of the relationship between 
25(OH)D2 and prostate cancer should be performed. Fourth, 
the vitamin D data were collected during the summer 
months in the northern latitudes and during the winter 
months in the southern latitudes for practical reasons. 
Seasonal variations in vitamin D levels could not be eval-
uated in this study. Fifth, positive association between 
25(OH)D2 levels and prostate cancer was limited to 
non-Hispanic white males. Further studies with larger sam-
ple sizes in other races are required to validate our findings 
in non-Hispanic white males.
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CONCLUSIONS
To our knowledge, this study is the first to suggest an 
association between 25(OH)D2 levels and prostate cancer in 
non-Hispanic white males. This study revealed a positive 
association between vitamin D, especially 25(OH)D2, and 
prostate cancer, however, vitamin D was not associated with 
PSA level. Further studies should be performed to inves-
tigate the role of 25(OH)D2 in prostate cancer.
CONFLICT OF INTEREST
The authors claim no conflicts of interest.
REFERENCES
1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 
357:266-81.
2. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, 
Neuhauser ML, et al. Plasma vitamin D and prostate can-
cer risk: results from the Selenium and Vitamin E Cancer 
Prevention Trial. Cancer Epidemiol Biomarkers Prev 
2014;23:1494-504.
3. Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, 
Torkko KC, et al. Serum 25-hydroxyvitamin D concen-
trations and risk of prostate cancer: results from the 
Prostate Cancer Prevention Trial. Cancer Epidemiol 
Biomarkers Prev 2014;23:1484-93.
4. Tuohimaa P, Lyakhovich A, Aksenov N, Pennanen P, 
Syvälä H, Lou YR, et al. Vitamin D and prostate cancer. 
J Steroid Biochem Mol Biol 2001;76:125-34.
5. Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, et al. 
Positive association between circulating 25-hydrox-
yvitamin D levels and prostate cancer risk: new findings 
from an updated meta-analysis. J Cancer Res Clin Oncol 
2014;140:1465-77.
6. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. 
CA Cancer J Clin 2014;64:9-29.
7. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum 
E, Hallmans G, et al. Both high and low levels of blood 
vitamin D are associated with a higher prostate cancer 
risk: a longitudinal, nested case-control study in the Nordic 
countries. Int J Cancer 2004;108:104-8.
8. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle 
EP, Catalona WJ, et al. NCCN Guidelines Insights: 
Prostate Cancer Early Detection, Version 2.2016. J Natl 
Compr Canc Netw 2016;14:509-19.
9. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, 
Clinton SK, et al. The 2011 report on dietary reference in-
takes for calcium and vitamin D from the Institute of 
Medicine: what clinicians need to know. J Clin Endocrinol 
Metab 2011;96:53-8.
10. Fleet JC. Molecular actions of vitamin D contributing to 
cancer prevention. Mol Aspects Med 2008;29:388-96.
11. Holick MF. Vitamin D: its role in cancer prevention and 
treatment. Prog Biophys Mol Biol 2006;92:49-59.
12. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, 
Virtamo J, et al. Serum 25-hydroxy vitamin D and prostate 
cancer risk in a large nested case-control study. Cancer 
Epidemiol Biomarkers Prev 2011;20:1850-60.
13. Park SY, Cooney RV, Wilkens LR, Murphy SP, 
Henderson BE, Kolonel LN. Plasma 25-hydroxyvitamin D 
and prostate cancer risk: the multiethnic cohort. Eur J 
Cancer 2010;46:932-6.
14. Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam 
AW, Tjønneland A, et al. Serum vitamin D and risk of 
prostate cancer in a case-control analysis nested within the 
European Prospective Investigation into Cancer and 
Nutrition (EPIC). Am J Epidemiol 2009;169:1223-32.
15. Pettifor JM, Bikle DD, Cavaleros M, Zachen D, Kamdar 
MC, Ross FP. Serum levels of free 1,25-dihydroxyvitamin 
D in vitamin D toxicity. Ann Intern Med 1995;122:511-3.
16. Vieth R, Pinto TR, Reen BS, Wong MM. Vitamin D poi-
soning by table sugar. Lancet 2002;359:672.
17. Vieth R. Vitamin D and cancer mini-symposium: the risk 
of additional vitamin D. Ann Epidemiol 2009;19:441-5.
18. Schwartz GG, Oeler TA, Uskoković MR, Bahnson RR. 
Human prostate cancer cells: inhibition of proliferation by 
vitamin D analogs. Anticancer Res 1994;14:1077-81.
19. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin 
D3, analogs on human prostate cancer cell lines: compar-
ison with 1,25-dihydroxyvitamin D3. Endocrinology 1995; 
136:20-6.
20. Liu G, Oettel K, Ripple G, Staab MJ, Horvath D, Alberti 
D, et al. Phase I trial of 1alpha-hydroxyvitamin d(2) in pa-
tients with hormone refractory prostate cancer. Clin 
Cancer Res 2002;8:2820-7.
21. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, 
Trump DL. Phase II trial of oral 1,25-dihydroxyvitamin D 
(calcitriol) in hormone refractory prostate cancer. Urol 
Oncol 1995;1:195-8.
22. Ahonen MH, Tenkanen L, Teppo L, Hakama M, 
Tuohimaa P. Prostate cancer risk and prediagnostic serum 
25-hydroxyvitamin D levels (Finland). Cancer Causes 
Control 2000;11:847-52.
23. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, 
Hedlund TE, et al. The human prostatic carcinoma cell line 
LNCaP expresses biologically active, specific receptors for 
1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992;52: 
515-20.
24. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, 
Jee Soo Park, et al：Prostate Cancer and 25-Hydroxyvitamin D2  39
Holick MF. The in vitro evaluation of 25-hydroxyvitamin 
D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as ther-
apeutic agents for prostate cancer. Clin Cancer Res 2000; 
6:901-8.
25. Anic GM, Albanes D, Rohrmann S, Kanarek N, Nelson 
WG, Bradwin G, et al. Association between serum 
25-hydroxyvitamin D and serum sex steroid hormones 
among men in NHANES. Clin Endocrinol (Oxf) 2016;85: 
258-66.
26. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami 
HO, Wolk A. Dairy products, calcium, phosphorous, vita-
min D, and risk of prostate cancer (Sweden). Cancer 
Causes Control 1998;9:559-66.
27. Tzonou A, Signorello LB, Lagiou P, Wuu J, Trichopoulos 
D, Trichopoulou A. Diet and cancer of the prostate: a 
case-control study in Greece. Int J Cancer 1999;80:704-8.
28. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, 
Fakhrabadi-Shokoohi D, Giovannucci EL, et al. Calcium, 
dairy products, and risk of prostate cancer in a prospective 
cohort of United States men. Cancer Epidemiol Biomarkers 
Prev 2003;12:597-603.
29. Yoo C, Kim CS. Complementary and Alternative 
Medicine(CAM) in Urology. Korean J Urol 2008;49:193- 
202.
30. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis 
V, Mouw T, et al. Prospective study of adiposity and 
weight change in relation to prostate cancer incidence and 
mortality. Cancer 2007;109:675-84.
31. MacInnis RJ, English DR. Body size and composition and 
prostate cancer risk: systematic review and meta-re-
gression analysis. Cancer Causes Control 2006;17:989- 
1003.
